GPA 512

CAS No. 1808115-35-6

GPA 512( GPA512 | GPA-512 )

Catalog No. M12766 CAS No. 1808115-35-6

The orally bioavailable prodrug of Galiellalactone, a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GPA 512
  • Note
    Research use only, not for human use.
  • Brief Description
    The orally bioavailable prodrug of Galiellalactone, a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes.
  • Description
    The orally bioavailable prodrug of Galiellalactone, a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes; increases the plasma exposure of the active parent compound 20-fold compared to Galiellalactone; significantly reduces tumor growth in DU145 xenograft tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GPA512 | GPA-512
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    STAT
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1808115-35-6
  • Formula Weight
    371.448
  • Molecular Formula
    C17H25NO6S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@H]1C[C@@H](CC[C@H]2OC3=O)[C@]2(O)C3[C@@H]1SC[C@H](NC(C)=O)C(OC)=O
  • Chemical Name
    methyl N-acetyl-S-((2aR,2a1S,4aR,6S,7R,7aS)-2a1-hydroxy-6-methyl-1-oxodecahydroindeno[1,7-bc]furan-7-yl)-L-cysteinate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Escobar Z, et al. J Med Chem. 2016 May 26;59(10):4551-62.
molnova catalog
related products
  • HO-3867

    A synthetic curcuminoid that selectively inhibits STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs.

  • Palivizumab

    Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

  • Ziresovir

    Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.